A bibliometric analysis on KRAS, a targeted marker for blockbuster clinical drugs.
This study aims to provide an overview of research hotspots and trends in KRAS, a key star gene which has been paid special attention to in the field of cancer.
APA
Guo Z, Zhao S, et al. (2025). A bibliometric analysis on KRAS, a targeted marker for blockbuster clinical drugs.. Cancer treatment and research communications, 45, 101001. https://doi.org/10.1016/j.ctarc.2025.101001
MLA
Guo Z, et al.. "A bibliometric analysis on KRAS, a targeted marker for blockbuster clinical drugs.." Cancer treatment and research communications, vol. 45, 2025, pp. 101001.
PMID
40972308
Abstract
This study aims to provide an overview of research hotspots and trends in KRAS, a key star gene which has been paid special attention to in the field of cancer. Publications on KRAS were searched in the Web of Science Core Collection database. VOSviewer 1.6.16 and R package "bibliometrix" were used for bibliometric analyses. A total of 23,758 publications were identified, including 19,325 original articles and 2913 reviews. A sharp increase of the publications number was found since the year 2016 by time trend analysis. The top 3 countries/regions with the highest number of publications were the United States, China and Europe. Most active organizations were from Europe and the USA. Keywords co-occurrence analysis showed four clusters of KRAS, including the role and molecular mechanism of KRAS in the process of cancer development, especially pancreatic cancer, studies on the characteristics and clinical value of KRAS in colorectal cancer, the role characteristics of KRAS in the occurrence of lung cancer and its clinical applications and research progress of clinical trials targeted KRAS. This study systematically elucidates emerging insights into the critical gene KRAS, providing a contemporary perspective on KRAS-driven oncogenesis.
MeSH Terms
Humans; Bibliometrics; Proto-Oncogene Proteins p21(ras); Biomarkers, Tumor; Neoplasms; Antineoplastic Agents; Molecular Targeted Therapy
같은 제1저자의 인용 많은 논문 (5)
- Discovery of novel and potent 2-aminopyrazine-based HPK1 inhibitors enhancing T-cell immunity against cancer.
- RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic‒epigenetic axis.
- Mitochondria Pathway Signature Predicts Prognosis and Therapeutic Response and Identifies REXO2 as a Crucial Regulator in Breast Cancer.
- The microbial metabolite I3A inhibits ferroptosis and the effectiveness of redox-based cancer therapy.
- Correction: Guo et al. Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. 2022, , 8264.